Literature DB >> 22658783

Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease.

Stephanie Coulon1, Sven Francque, Isabelle Colle, An Verrijken, Bram Blomme, Femke Heindryckx, Steffi De Munter, Janne Prawitt, Sandrine Caron, Bart Staels, Hans Van Vlierberghe, Luc Van Gaal, Anja Geerts.   

Abstract

The liver is a major target of injury in obese patients. Non-alcoholic fatty liver disease (NAFLD) is present in 60-90% of obese Americans and can range from simple steatosis to the more severe non-alcoholic steatohepatitis (NASH). The onset of a chronic inflammatory reaction marks the progression from simple steatosis to NASH and the expansion of adipose tissue is strongly associated with angiogenesis. Therefore, we determined the serum concentration of inflammatory [tumor necrosis factor alpha (TNFα) and interleukin 6 (IL6)] and angiogenic [vascular endothelial growth factor A (VEGF)] cytokines and soluble VEGF receptors 1 and 2 (sVEGFR1, sVEGFR2) in the serum of an obese population with simple steatosis and NASH compared to healthy controls. Moreover, we determined the TNFα, IL6, VEGF, VEGFR1 and VEGFR2 gene expression in the liver of these simple steatosis and NASH patients. The population consisted of 30 obese patients, which were diagnosed with simple steatosis and 32 patients with NASH and compared to 30 age-and-sex matched healthy controls. Mean serum TNFα levels were elevated in the serum of simple steatosis and NASH patients compared to healthy controls, reaching significance in NASH patients. IL6 was significantly increased in simple steatosis and NASH patients compared to the healthy controls. VEGF levels were significantly elevated in patients with simple steatosis and borderline significantly elevated in NASH patients compared to the serum levels of healthy control subjects. The concentration of sVEGFR1 was significantly increased in serum of simple steatosis and NASH patients compared to controls. sVEGFR2 concentration was not significantly different in the three groups. TNFα mRNA expression was higher in NASH patients compared to simple steatosis patients. Hepatic gene expression of VEGF, VEGFR1 and VEGFR2 were slightly decreased in NASH patients compared to simple steatosis patients. These data indicate the involvement of inflammatory (TNFα and IL6), angiogenic (VEGF) cytokines and sVEGFR1 in the pathophysiology of NAFLD.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22658783     DOI: 10.1016/j.cyto.2012.05.001

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  39 in total

Review 1.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

2.  Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.

Authors:  Sofia de Oliveira; Ruth A Houseright; Alyssa L Graves; Netta Golenberg; Benjamin G Korte; Veronika Miskolci; Anna Huttenlocher
Journal:  J Hepatol       Date:  2018-12-18       Impact factor: 25.083

Review 3.  Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.

Authors:  Jun Wei Lim; John Dillon; Michael Miller
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

4.  Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: Results from the Multi-Ethnic Study of Atherosclerosis.

Authors:  Tracey G Simon; Maria Esther Perez Trejo; Robyn McClelland; Ryan Bradley; Michael J Blaha; Irfan Zeb; Kathleen E Corey; Matthew J Budoff; Raymond T Chung
Journal:  Int J Cardiol       Date:  2018-05-15       Impact factor: 4.164

Review 5.  The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease.

Authors:  Sven M Francque
Journal:  Eur Cardiol       Date:  2014-07

Review 6.  Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background.

Authors:  Giulia Ganzetti; Anna Campanati; Elisa Molinelli; Annamaria Offidani
Journal:  World J Cardiol       Date:  2016-02-26

7.  Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease.

Authors:  S Lefere; F Van de Velde; L Devisscher; M Bekaert; S Raevens; X Verhelst; Y Van Nieuwenhove; M Praet; A Hoorens; C Van Steenkiste; H Van Vlierberghe; B Lapauw; A Geerts
Journal:  Int J Obes (Lond)       Date:  2017-05-02       Impact factor: 5.095

Review 8.  Tumor promoters: from chemicals to inflammatory proteins.

Authors:  Hirota Fujiki; Eisaburo Sueoka; Masami Suganuma
Journal:  J Cancer Res Clin Oncol       Date:  2013-06-12       Impact factor: 4.553

9.  Chronic consumption of fructose in combination with trans fatty acids but not with saturated fatty acids induces nonalcoholic steatohepatitis with fibrosis in rats.

Authors:  Sugeedha Jeyapal; Uday Kumar Putcha; Venkata Surekha Mullapudi; Sudip Ghosh; Anil Sakamuri; Suryam Reddy Kona; Sai Santosh Vadakattu; Chandana Madakasira; Ahamed Ibrahim
Journal:  Eur J Nutr       Date:  2017-07-04       Impact factor: 5.614

10.  The Potential Protective Role of RUNX1 in Nonalcoholic Fatty Liver Disease.

Authors:  Laia Bertran; Angela Pastor; Marta Portillo-Carrasquer; Jessica Binetti; Carmen Aguilar; Salomé Martínez; Margarita Vives; Fàtima Sabench; José Antonio Porras; David Riesco; Daniel Del Castillo; Cristóbal Richart; Teresa Auguet
Journal:  Int J Mol Sci       Date:  2021-05-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.